Thursday , June 17 2021

Covid-19 – Molnupiravir, a drug that stops the spread of coronavirus in 24 hours



While the world is waiting for vaccines, new hope is emerging in the fight against Covid-19 as a molnupiravir research drug. Administered orally, it would block the transmission of the virus within 24 to 36 hours. What eliminated the pandemic?

If the vaccine is the most promising hope in the fight against coronavirus, the University of Georgia (USA) announced this Thursday, December 3, that it has progressed in the development of oral administration or the advancement of a drug.

In an article published in the journal Nature online, researchers at Emory University said that the antiviral antiviral (molnupiravir with its trade name) MK-2282 / EIDD-2081 is a major breakthroughremoves the infection in less than 24 hours.

“Orally SARS-CoV-2 is the first demonstration of a drug capable of rapidly blocking transmission, the rules of the game can be reversed,” the researchers explained in their findings.

Patients with Covid-19 may become infectious within 24-36 hours

To date, the drug has been “tested in furs that effectively transmit the virus, with minimal clinical signs similar to that prevalent in the young human adult population.”

The researchers acknowledge that the antiviral efficacy of molnupiravir “in humans” is “still unknown.” However, they point out that “if the SARS-CoV-2 ferret predicts data on human transmission, patients with Covid-19 may become infectious within 24 to 36 hours. Oral treatment may begin.”

Shortly after infection, molnupiravir would have three advantages: “it reduces the risk of developing serious illnesses and accelerates recovery, avoids isolation and confinement, and eventually blocks the set very quickly.” In short, a serious asset to end the epidemic.

Tests in humans have already begun and are now in Phase II. No studies have yet been published on these first tests.

The research released this Thursday will be examined by the scientific world before publication. The release of this experimental drug has not yet been scheduled.

Until then, Ridgeback Biotherapeutics and Merck, the laboratories associated with the project, will have to remove any doubts that have arisen from previous versions of molnupiravir that would have mutagenic properties by creating congenital malformations.


Source link